Skip to content
MarketScale
‹ Back to IndustriesSciences

Made in America with Garrett Metal Detectors: Coming January 7

In 1964, Charles Garrett’s lifetime hobby turned into his life’s work. An avid treasure hunter and inventor, Garrett and his wife, Eleanor, founded Garrett Metal Detectors in their garage. “He had pretty much finished the first prototype, and it was really awesome, and it was making all the sounds that it normally does, but they…

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Software And Technology · Bob Podhrasky VideoTyler Kern VideoVaughn Garrett VideoZach Werblo Video
Share
Made in America with Garrett Metal Detectors: Coming January 7

Key takeaways

01

In 1964, Charles Garrett’s lifetime hobby turned into his life’s work.

02

An avid treasure hunter and inventor, Garrett and his wife, Eleanor, founded Garrett Metal Detectors in their garage.

03

“He had pretty much finished the first prototype, and it was really awesome, and it was making all the sounds that it normally does, but they…


In 1964, Charles Garrett’s lifetime hobby turned into his life’s work. An avid treasure hunter and inventor, Garrett and his wife, Eleanor, founded Garrett Metal Detectors in their garage.

“He had pretty much finished the first prototype, and it was really awesome, and it was making all the sounds that it normally does, but they were keeping my mom up at midnight,” said Vaughn Garrett, Senior Vice President of Marketing. “So she stepped out into the garage and said, ‘Charles, put that detector on the market or forget it.’ And the light bulb went off, and they formed the Garrett Metal Detector company at that point.”

Fifty-six years after it began, the company is the still pursuing its mission to provide top-of-the-line metal detectors.

Specializing in treasure hunting devices and security-screening machines, Garrett products have interacted with millions of people worldwide in various capacities over the past five decades.

On this episode of Made in America, we head to Garland, Texas to see how one of Garrett’s flagship products is brought to life. COO Bob Podhrasky, who has been with the company for more than 50 years, gives us the details straight from the assembly line.

While the company now serves clients all over the globe, including the Olympic games, it remains an important figure in its local area just outside of Dallas.

“We’ll continue to do it here. There’s no reason to move,” Vaughn Garrett said.

Tune in January 7th for the full episode. Click here to subscribe now!

Watch Previous Episodes

About the author

SA
Software And Technology

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Expert

SA
Software And Technology

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512